Publications by authors named "Melissa J McIlraith"
Article Synopsis
- Long-term safety of adalimumab, an anti-TNF drug, was analyzed based on data from over 23,000 patients across multiple diseases including rheumatoid arthritis and Crohn's disease.
- The study found that infections were the most common serious adverse events, with overall malignancy and death rates similar to those in the general population, although some cancer rates were elevated in specific conditions.
- No new safety concerns were identified, indicating that adalimumab's safety profile remains consistent with what is already known about the anti-TNF class of medications.
Background: Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis.
Methods: Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with nonsteroidal antiinflammatory drugs underwent stratification according to methotrexate use and received 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for 16 weeks.